AddLife (ALIF) investor relations material

Executive summary

• Strong third quarter with solid organic growth, significant EBITDA/EBITA margin improvement, and reduced net debt/EBITDA to 2.9, driven by both Labtech and Medtech segments.

• Currency-adjusted growth reached 7% (6% organic, 1% from acquisitions), with healthy customer demand and cost control across business areas.

• Profit before tax increased by 164% and profit after tax by 228% year-over-year, supported by lower tax rates and interest costs.

• Net sales for Q3 rose 4% year-over-year to SEK 2,429m, with EBITA excluding one-off costs up 17% to SEK 270m and margin at 11.1%.

• For the nine months, net sales grew 3% to SEK 7,709m, EBITA excl. one-offs up 12% to SEK 920m, and profit after tax up 89% to SEK 302m.

Financial highlights

• Total sales growth was 4% year-over-year, with organic growth at 6% and acquired growth at 1%; net sales reached SEK 2,429m.

• EBITDA/EBITA margin improved to 11.1% from 9.8% last year; year-to-date EBITDA/EBITA margin at 11.9% versus 11% last year.

• Adjusted EBITDA/EBITA growth was 20% year-over-year, excluding SEK 7 million in revaluation and restructuring costs.

• Operating cash flow for the quarter was SEK 145 million; accumulated operating cash flow SEK 504 million, up from SEK 429 million last year.

• Cash conversion remained above 90%, with a focus on inventory reduction and working capital efficiency.

Outlook and guidance

• Strengthened financial position and reduced leverage enable increased acquisition activity moving forward.

• Inventory build-up in anticipation of strong Q4 sales; accounts receivable expected to normalize in Q4.

• Companies are well positioned for long-term growth and profitability, with ongoing efficiency initiatives and a focus on advanced products.